Evaluation and management of postpartum hemorrhage: Consensus from an international expert panel

Transfusion

Volumn 54, Issue 7, 2014, Pages 1756-1768

  Abdul Kadir, Rezan ^a   McLintock, Claire ^a   Ducloy, Anne Sophie ^b   El Refaey, Hazem ^c   England, Adrian ^d   Federici, Augusto B ^e   Grotegut, Chad A ^f   Halimeh, Susan ^g   Herman, Jay H ^h   Hofer, Stefan ⁱ   James, Andra H ^j   Kouides, Peter A ^k   Paidas, Michael J ^l   Peyvandi, Flora ^m   Winikoff, Rochelle ⁿ  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Department of Obstetrics and Gynecology Duke University School of Medicine ^*  (Germany)

^h THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF VIRGINIA   (United States)

^k ROCHESTER GENERAL HOSPITAL   (United States)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ UNIVERSITY OF MONTREAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; ERGOMETRINE PLUS OXYTOCIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; HEMOSTATIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OXYTOCIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; UTEROTONIC AGENT;

ALGORITHM; ALLOIMMUNIZATION; ARTICLE; BERNARD SOULIER DISEASE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BREAST FEEDING; CLINICAL ASSESSMENT; CONSENSUS; CRYOPRECIPITATE; CRYSTALLOID; DISEASE CARRIER; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; EVALUATION STUDY; FIBRINOGEN BLOOD LEVEL; GENITAL INJURY; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGIC SHOCK; HUMAN; HYPOFIBRINOGENEMIA; HYSTERECTOMY; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTRAUTERINE BALLOON; LABOR MANAGEMENT; LABOR STAGE 3; MATERNAL MORBIDITY; MATERNAL MORTALITY; META ANALYSIS; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PLATE COUNT; POINT OF CARE TESTING; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETAINED PLACENTA; RISK ASSESSMENT; SPONTANEOUS PLACENTAL DELIVERY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOSIS PREVENTION; UTERINE ATONY; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COMPONENT TRANSFUSION; EXPERT TESTIMONY; FEMALE; HEMOSTATICS; HUMANS; LABOR, OBSTETRIC; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PROFESSIONAL PRACTICE; RISK FACTORS;

EID: 84904498377     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12550     Document Type: Article

References (88)

1. UN. The millennium development goals report. [cited 2011 Nov 30]. Available from: http://www.un.org/milleniumgoals/maternal.shtml
2. Oyelese Y, Ananth CV,. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol 2010; 53: 147-156.
3. Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-1074.
4. James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201: 12 e1-128.
5. James AH, Kouides PA, Abdul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011; 158: 124-134.
6. ACOG. Reading the medical literature: applying evidence to practice. [cited 2013 May 01]. Available from: http://www.acog.org/Resources-And- Publications/Department-Publications/Reading-The-Medical-Literature
7. ACOG. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol 2006; 108: 1039-1047.
8. Rath WH,. Postpartum hemorrhage-update on problems of definitions and diagnosis. Acta Obstet Gynecol Scand 2011; 90: 421-428.
9. World Health Organization. WHO guidelines for the management of postpartum haemorrhage and retained placenta. 1-62; 2009. [cited 2011 Nov 30]. Available from: http://whqlibdoc.who.int/publications/2009/9789241598514-eng.pdf
10. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 52: Prevention and management of postpartum haemorrhage. 2009 (revised 2011).
11. Bateman BT, Berman MF, Riley LE, et al. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110: 1368-1373.
12. Al-Zirqi I, Vangen S, Forsen L, et al. Prevalence and risk factors of severe obstetric haemorrhage. BJOG 2008; 115: 1265-1272.
13. Bais JM, Eskes M, Pel M, et al. Postpartum haemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard (> or =500ml) and severe (> or =1000ml) postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol 2004; 115: 166-172.
14. Belghiti J, Kayem G, Dupont C, et al. Oxytocin during labour and risk of severe postpartum haemorrhage: a population-based, cohort-nested case-control study. BMJ Open 2011; 1: e000514.
15. Combs CA, Murphy EL, Laros RK Jr,. Factors associated with hemorrhage in cesarean deliveries. Obstet Gynecol 1991; 77: 77-82.
16. Jolly M, Sebire N, Harris J, et al. The risks associated with pregnancy in women aged 35 years or older. Hum Reprod 2000; 15: 2433-2437.
17. Rouse DJ, MacPherson C, Landon M, et al. Blood transfusion and cesarean delivery. Obstet Gynecol 2006; 108: 891-897.
18. Sosa CG, Althabe F, Belizan JM, et al. Risk factors for postpartum hemorrhage in vaginal deliveries in a Latin-American population. Obstet Gynecol 2009; 113: 1313-1319.
19. Stones RW, Paterson CM, Saunders NJ,. Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol 1993; 48: 15-18.
20. Kadir RA, Economides DL, Braithwaite J, et al. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997; 104: 803-810.*et al.
21. Huq FY, Kadir RA,. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011; 17 (Suppl 1): 20-30.
22. Greer IA, Lowe GD, Walker JJ, et al. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 909-918.
23. Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314-321.
24. Ramsahoye BH, Davies SV, Dansani H, et al. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140-144.
25. James AH, Jamison MG,. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007; 5: 1165-1169.
26. Begley CM, Gyte GM, Murphy DJ, et al. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev 2010;(7): CD007412.
27. Goodwin TM,. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989; 44: 157-161.
28. Noia G, De Carolis S, De Stefano V, et al. Factor V deficiency in pregnancy complicated by Rh immunization and placenta previa. A case report and review of the literature. Acta Obstet Gynecol Scand 1997; 76: 890-892.
29. Kulkarni AA, Lee CA, Kadir RA,. Pregnancy in women with congenital factor VII deficiency. Haemophilia 2006; 12: 413-416.
30. Teixeira PS, Oliveira PS, Guerra JC, et al. Factor X deficiency and pregnancy: case report and counselling. Haemophilia 2012; 18: e11-12.
31. Burrows RF, Ray JG, Burrows EA,. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55: 103-108.
32. Siddiq S, Clark A, Mumford A,. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e858-869.
33. Peitsidis P, Datta T, Pafilis I, et al. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010; 16: 584-591.
34. Peyvandi F, Menegatti M, Siboni SM,. Post-partum hemorrhage in women with rare bleeding disorders. Thromb Res 2011; 127 (Suppl 3): S116-119.
35. Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95: 75-87.
36. Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-633.
37. Ranasinghe E, Walton JD, Hurd CM, et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001; 113: 40-42.
38. Group TPS. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-1869.
39. Kadir RA, Kingman CE, Chi C, et al. Is primary postpartum haemorrhage a good predictor of inherited bleeding disorders? Haemophilia 2007; 13: 178-181.
40. Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-2066.
41. Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 2063-2065.
42. Tosetto A, Castaman G, Plug I, et al. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9: 1143-1148.
43. Cotter AM, Ness A, Tolosa JE,. Prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev 2001;(10): CD001808.
44. McDonald S, Abbott JM, Higgins SP,. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004;(1): CD000201.
45. Ducloy-Bouthors AS, Jude B, Duhamel A, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; 15: R117.
46. Bose P, Regan F, Paterson-Brown S,. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions. BJOG 2006; 113: 919-924.
47. Zhang WH, Deneux-Tharaux C, Brocklehurst P, et al. Effect of a collector bag for measurement of postpartum blood loss after vaginal delivery: cluster randomised trial in 13 European countries. BMJ 2010; 340: c293.
48. Singh S, McGlennan A, England A, et al. A validation study of the CEMACH recommended modified early obstetric warning system (MEOWS). Anaesthesia 2012; 67: 12-18.
49. ® thromboelastography. [cited 2012 Sep 01]. Available from: http://www.rotem.de/site/index.php?option=com- content&view=article&id=65&Itemid=19&lang=en
50. Bischof D, Dalbert S, Zollinger A, et al. Thrombelastography in the surgical patient. Minerva Anestesiol 2010; 76: 131-137.
51. Kashuk JL, Moore EE, Sabel A, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery 2009; 146: 764-772; discussion 772-4.
52. Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010; 252: 434-442; discussion 43-4.
53. Davenport R, Manson J, De'Ath H, et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med 2011; 39: 2652-2658.
54. Schochl H, Cotton B, Inaba K, et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care 2011; 15: R265.
55. Scottish Obstetric Guidelines and Audit Project. The management of postpartum haemorrhage: a clinical practice guideline for professionals involved in maternity care in Scotland. 1998. [cited 2012 Sep 01]. Available from: http://www.nhshealthquality.org/nhsqis/files/MATERNITYSERVICES- PostpartumHaemorrage-SPCERH6-JUN98.pdf
56. Levy GG, Carbonne B, Courtois F, et al. Recommandations pour la pratique Clinique Hémorragies du post-partum immediate. J Gynecol Obstet Biol Reprod (Paris) 2004; 33 (Suppl n8): 4S1-4S136.
57. Alfirevic Z, Elbourne D, Pavord S, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol 2007; 110: 1270-1278.
58. Phillips LE, McLintock C, Pollock W, et al. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009; 109: 1908-1915.
59. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
60. Clinicaltrials.gov. World Maternal Antifibrinolytic Trial (WOMAN). NCT00872469 2012.
61. Briggs GG, Freeman RK, Yaffe SJ,. Tranexamic acid. Drugs in pregnancy and lactation. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
62. Bremme KA,. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168.
63. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63: 805-813.
64. Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma 2009; 66: 41-48; discussion 8-9.
65. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447-458.
66. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5: 266-273.
67. Cortet M, Deneux-Tharaux C, Dupont C, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth 2012; 108: 984-989.
68. Peyvandi F, Biguzzi E, Franchi F, et al. Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. J Thromb Haemost 2012; 10: 1451-1453.
69. Theusinger OM, Baulig W, Seifert B, et al. Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Br J Anaesth 2011; 106: 505-511.
70. Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261-274.
71. Caudill JS, Nichols WL, Plumhoff EA, et al. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion 2009; 49: 765-770.
72. Weiner AE, Reid DE, Roby CC,. Coagulation defects associated with premature separation of the normally implanted placenta. Am J Obstet Gynecol 1950; 60: 379-386.
73. Swedish Society on Thrombosis and Haemostasis (SSTH). Haemostasis in cases of severe haemorrhage: a treatment programme developed by a work group of the Swedish Society on Thrombosis and Haemostasis. 2010. [cited 2012 Jun 8]. Available from: http://www.skane.se/upload/Webbplatser/UMAS/VERKSAMHETER%20UMAS/ Hemostas2-web-linked,%20110325%20final.pdf
74. Henrich W, Surbek D, Kainer F, et al. Diagnosis and treatment of peripartum bleeding. J Perinat Med 2008; 36: 467-478.
75. Fenger-Eriksen C, Ingerslev J, Sorensen B,. Fibrinogen concentrate-a potential universal hemostatic agent. Expert Opin Biol Ther 2009; 9: 1325-1333.
76. Bell SF, Rayment R, Collins PW, et al. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth 2010; 19: 218-223.
77. Glover NJ, Collis RE, Collins P,. Fibrinogen concentrate use during major obstetric haemorrhage. Anaesthesia 2010; 65: 1229-1230.
78. Franchini M, Lippi G, Franchi M,. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007; 114: 8-15.
79. Haynes J, Laffan M, Plaat F,. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth 2007; 16: 40-49.
80. Hossain N, Shansi T, Haider S, et al. Use of recombinant activated factor VII for massive postpartum hemorrhage. Acta Obstet Gynecol Scand 2007; 86: 1200-1206.
81. Bouma LS, Bolte AC, van Geijn HP,. Use of recombinant activated factor VII in massive postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol 2008; 137: 172-177.
82. Kobayashi T, Nakabayashi M, Yoshioka A, et al. Recombinant activated factor VII (rFVIIa/NovoSeven(R)) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan. Int J Hematol 2012; 95: 57-63.
83. Lewis NR, Brunker P, Lemire SJ, et al. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 2009; 49: 689-695.
84. Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184: 104-110.
85. Jacobsen AF, Skjeldestad FE, Sandset PM,. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium-a register-based case-control study. Am J Obstet Gynecol 2008; 198: 233 e1-2337.
86. James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194: 1311-1315.
87. Faltas B, Kouides PA,. Update on perioperative bridging in patients on chronic oral anticoagulation. Expert Rev Cardiovasc Ther 2009; 7: 1533-1539.
88. McLintock C, Brighton T, Chunilal S, et al. Recommendations for the prevention of pregnancy-associated venous thromboembolism. Aust N Z J Obstet Gynaecol 2011; 52: 3-13.